Geron Moves Up, Sucampo Wins FDA Approval to Discontinue Warnings: Health Care Business Update

Shares of Geron Corporation (NASDAQ:GERN) moved up on the day on word that the company has discontinued development of GRN1005, its peptide-drug conjugate designed to treat cancers in the brain. In the future, the firm will concentrate on the development of imetelstat, which is its telomerase inhibitor, in hematologic myeloid malignancies and in patients with solid tumors that have short telomeres.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

In a Monday Release,  PDL BioPharma (NASDAQ:PDLI) today announced that Vice President and Chief Financial Officer  Bruce Tomlinson has resigned his position due to personal reasons, effective November 30th.  The firm will begin a search for a new officer to fill the position.

Sucampo Pharmaceuticals (NASDAQ:SCMP) reported in a Monday release that the Company received a supplement approval from the FDA which removes pregnancy warnings and precautions and clarifies information in connection with the use of Amitiza (lubiprostone) by pregnant and/or nursing women. Also, the FDA broadened the labeling text of the Mechanism of Action section in the prescribing information for the drug. Amitiza is cleared for the treatment of chronic idiopathic constipation in adults (24 mcg twice daily) and irritable bowel syndrome with constipation in women 18 years and older (8 mcg twice daily).

Don’t Miss: Will This Purchase Boost Sales for GlaxoSmithKline?